CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain

 
• By Derrick Gingery

US FDA has not named permanent heads of several offices within the new Office of Therapeutic Products, the only super office in the Center for Biologics Evaluation and Research.

reorganization
Primary contacts for applications already under review will not change now that OTAT has been reorganized and renamed OTP. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies